MyOme, Inc., a leading clinical genetics innovation company, and Broad Clinical Labs (BCL), the world expert in whole genome sequencing (WGS) are announcing a partnership to support the Southern ...
In a major step toward expanding patient access, MyOme is highlighting its strategic partnership with Natera (NASDAQ: NTRA) to launch Zenith™ powered by MyOme. Zenith is a premium exome and genome ...
MyOme’s Rare Disease diagnostic product addresses these challenges by providing a more comprehensive WGS-based approach, promoting efficient and accurate diagnosis, leading to improved patient ...
MENLO PARK, Calif., Feb. 27, 2025 /PRNewswire/ — MyOme, Inc., a leading clinical whole genome testing and polygenic risk modelling (PRS) company, is proud to announce the launch of its coronary artery ...
MyOme is a genomics company advancing precision health through whole-genome sequencing and AI-integrated risk models. Its flagship solution, MyOme Proactive Health, provides single-gene risk insights, ...
Zacks Investment Research on MSN
NTRA debuts Zenith Genomics next-gen sequencing test for rare diseases
Natera NTRA announced the commercial launch of Zenith genomics, a next-generation whole genome sequencing assay designed to ...
MENLO PARK, Calif. and CINCINNATI, Dec. 3, 2025 /PRNewswire/ -- MyOme, a leading clinical whole-genome testing and polygenic risk modelling (PRS) company, today announced a strategic partnership with ...
Findings come as ACC/AHA guidelines recognize polygenic risk as an ASCVD risk enhancer MENLO PARK, Calif., March 20, 2026 /PRNewswire/ -- MyOme, a leader in clinical whole-genome analysis and ...
The American College of Medical Genetics and Genomics (ACMG) announced today that the eighth annual Medical Genetics Awareness Week, sponsored by MyOme, will be held March 10–14, 2026 Medical genetics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results